{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T00:43:21Z","timestamp":1789173801944,"version":"build-2803163510"},"reference-count":80,"publisher":"Bentham Science Publishers Ltd.","issue":"1","funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III, Proyectos de Investigaci\u00f3n en Salud","doi-asserted-by":"publisher","award":["PI16\/01378"],"award-info":[{"award-number":["PI16\/01378"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III, Proyectos de Investigaci\u00f3n en Salud","doi-asserted-by":"publisher","award":["PI19\/01453"],"award-info":[{"award-number":["PI19\/01453"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003329","name":"Ministerio de Econom\u00eda y Competitividad of Spain","doi-asserted-by":"publisher","award":["CP20\/00018"],"award-info":[{"award-number":["CP20\/00018"]}],"id":[{"id":"10.13039\/501100003329","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMC"],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:sec>\n<jats:title>:<\/jats:title>\n<jats:p>Bacterial infections are among the leading causes of death worldwide. The\nemergence of antimicrobial resistance factors threatens the efficacy of all current antimicrobial\nagents, with some already made ineffective, and, as a result, there is an urgent\nneed for new treatment approaches. International organizations, such as the World\nHealth Organization and the European Centre for Diseases Control, have recognized infections\ncaused by multi-drug-resistant (MDR) bacteria as a priority for global health action.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>:<\/jats:title>\n<jats:p>Classical antimicrobial drug discovery involves in vitro screening for antimicrobial candidates,\nStructure-Activity Relationship analysis, followed by in vivo testing for toxicity.\nBringing drugs from the bench to the bedside involves huge expenditures in time and resources.\nThis, along with the relatively short window of therapeutic application for antibiotics\nattributed to the rapid emergence of drug resistance, has, at least until recently, resulted\nin a waning interest in antibiotic discovery among pharmaceutical companies. In\nthis environment, \u201crepurposing\u201d (defined as investigating new uses for existing approved\ndrugs) has gained renewed interest, as reflected by several recent studies, and may help\nto speed up the drug development process and save years of expensive research invested\nin antimicrobial drug development.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>:<\/jats:title>\n<jats:p>The goal of this review is to provide an overview of the scientific evidence on potential\nanthelmintic drugs targeting Gram-negative bacilli (GNB). In particular, we aim to: (i)\nhighlight the potential of anthelmintic drugs for treatments of GNB infections, (ii) review\ntheir mechanisms of action against these bacteria, (iii) summarize the outcome of preclinical\nstudies investigating approved anthelmintic drugs that target these bacteria, (iv) provide\ncritical challenges for further anthelmintic repurposing drugs development, and (v)\nlist the specific anthelmintic drugs that may be more likely to be repurposed.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0929867329666220714092916","type":"journal-article","created":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T12:06:10Z","timestamp":1657800370000},"page":"59-71","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Anthelmintic Drugs for Repurposing against Gram-Negative Bacilli\nInfections"],"prefix":"10.2174","volume":"30","author":[{"given":"Andrea Mir\u00f3","family":"Canturri","sequence":"first","affiliation":[{"name":"Clinical Unit of Infectious Diseases, Microbiology and Preventive Medicine, Virgen del Roc\u00edo University\nHospital, Seville, Spain"},{"name":"Institute of Biomedicine of Seville (IBiS), Virgen del Roc\u00edo University Hospital\/CSIC\/\nUniversity of Seville, Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9302-8384","authenticated-orcid":true,"given":"Younes","family":"Smani","sequence":"additional","affiliation":[{"name":"Clinical Unit of Infectious Diseases, Microbiology and Preventive Medicine, Virgen del Roc\u00edo University\nHospital, Seville, Spain"},{"name":"Institute of Biomedicine of Seville (IBiS), Virgen del Roc\u00edo University Hospital\/CSIC\/\nUniversity of Seville, Seville, Spain"},{"name":"Department of Molecular Biology and Biochemical Engineering,\nAndalusian Center of Developmental Biology, CSIC, University of Pablo de Olavide, Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/S1473-3099(17)30753-3","volume":"18","author":"Tacconelli E.","year":"2018","unstructured":"Tacconelli E.; Carrara E.; Savoldi A.; Harbarth S.; Mendelson M.; Monnet D.L.; Pulcini C.; Kahlmeter G.; Kluytmans J.; Carmeli Y.; Ouellette M.; Outterson K.; Patel J.; Cavaleri M.; Cox E.M.; Houchens C.R.; Grayson M.L.; Hansen P.; Singh N.; Theuretzbacher U.; Magrini N.; Aboderin A.O.; Al-Abri S.S.; Awang Jalil N.; Benzonana N.; Bhattacharya S.; Brink A.J.; Burkert F.R.; Cars O.; Cornaglia G.; Dyar O.J.; Friedrich A.W.; Gales A.C.; Gandra S.; Giske C.G.; Goff D.A.; Goossens H.; Gottlieb T.; Guzman Blanco M.; Hryniewicz W.; Kattula D.; Jinks T.; Kanj S.S.; Kerr L.; Kieny M-P.; Kim Y.S.; Kozlov R.S.; Labarca J.; Laxminarayan R.; Leder K.; Leibovici L.; Levy-Hara G.; Littman J.; Malhotra-Kumar S.; Manchanda V.; Moja L.; Ndoye B.; Pan A.; Paterson D.L.; Paul M.; Qiu H.; Ramon-Pardo P.; Rodr&#xED;guez-Ba&#xF1;o J.; Sanguinetti M.; Sengupta S.; Sharland M.; Si-Mehand M.; Silver L.L.; Song W.; Steinbakk M.; Thomsen J.; Thwaites G.E.; van der Meer J.W.M.; Van Kinh N.; Vega S.; Villegas M.V.; Wechsler-F&#xF6;rd&#xF6;s A.; Wertheim H.F.L.; Wesangula E.; Woodford N.; Yilmaz F.O.; Zorzet A.; Discovery, research, and development of new antibiotics: The WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis 2018,18(3),318-327","journal-title":"Lancet Infect Dis"},{"key":"ref=2","author":"O\u2019 Neill J.","year":"2016","unstructured":"O\u2019 Neill J.; Tackling drug-resistant infections globally: Final report and recommendations. Review on Antimicrobial resistance 2016","journal-title":"Review on Antimicrobial resistance"},{"key":"ref=3","year":"2021","unstructured":"Antimicrobial resistance.  Available from:  (Accessed date:17 November 2021).2021"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.jgar.2018.11.010","volume":"17","author":"Viderman D.","year":"2019","unstructured":"Viderman D.; Brotfain E.; Khamzina Y.; Kapanova G.; Zhumadilov A.; Poddighe D.; Bacterial resistance in the intensive care unit of developing countries: Report from a tertiary hospital in Kazakhstan. J Glob Antimicrob Resist 2019,17,35-38","journal-title":"J Glob Antimicrob Resist"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1080\/21548331.2021.1973825","volume":"49","author":"Simeon P.","year":"2021","unstructured":"Simeon P.; Godman B.; Kalemeera F.; Antibiotics\u2019 susceptibility patterns of bacterial isolates causing lower respiratory tract infections in ICU patients at referral hospitals in Namibia. Hosp Pract 2021,49(5),356-363","journal-title":"Hosp Pract"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"e01923-21","DOI":"10.1128\/aac.01923-21","volume":"66","author":"Blasco L.","year":"2022","unstructured":"Blasco L.; Bleriot I.; Gonz&#xE1;lez de Aledo M.; Fern&#xE1;ndez-Garc&#xED;a L.; Pacios O.; Oliveira H.; L&#xF3;pez M.; Ortiz-Cartagena C.; Fern&#xE1;ndez-Cuenca F.; Pascual &#xC1;.; Mart&#xED;nez-Mart&#xED;nez L.; Pach&#xF3;n J.; Azeredo J.; Tom&#xE1;s M.; Development of an Anti-Acinetobacter baumannii biofilm phage cocktail: Genomic adaptation to the host. Antimicrob Agents Chemother 2022,66(3),e01923-21","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1007\/s00253-017-8671-0","volume":"102","author":"Hegarty J.P.","year":"2018","unstructured":"Hegarty J.P.; Stewart D.B.; Advances in therapeutic bacterial antisense biotechnology. Appl Microbiol Biotechnol 2018,102(3),1055-1065","journal-title":"Appl Microbiol Biotechnol"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1021\/acsapm.1c01672","volume":"4","author":"Li Z.","year":"2022","unstructured":"Li Z.; Lu W.; Jia S.; Yuan H.; Backbone-regulated cationic conjugated polymers for combating and monitoring pathogenic bacteria. ACS Appl Polym Mater 2022,4(1),29-35","journal-title":"ACS Appl Polym Mater"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"41","DOI":"10.3389\/fmicb.2019.00041","volume":"10","author":"Mir&#xF3;-Canturri A.","year":"2019","unstructured":"Mir&#xF3;-Canturri A.; Ayerbe-Algaba R.; Smani Y.; Drug repurposing for the treatment of bacterial and fungal infections. Front Microbiol 2019,10,41","journal-title":"Front Microbiol"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1126\/science.1176667","volume":"325","author":"Fischbach M.A.","year":"2009","unstructured":"Fischbach M.A.; Walsh C.T.; Antibiotics for emerging pathogens. Science 2009,325(5944),1089-1093","journal-title":"Science"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1038\/nrd4675","volume":"14","author":"Brown D.","year":"2015","unstructured":"Brown D.; Antibiotic resistance breakers: Can repurposed drugs fill the antibiotic discovery void? Nat Rev Drug Discov 2015,14(12),821-832","journal-title":"Nat Rev Drug Discov"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/s41586-020-2286-9","volume":"583","author":"Gordon D.E.","year":"2020","unstructured":"Gordon D.E.; Jang G.M.; Bouhaddou M.; Xu J.; Obernier K.; White K.M.; O\u2019Meara M.J.; Rezelj V.V.; Guo J.Z.; Swaney D.L.; Tummino T.A.; H&#xFC;ttenhain R.; Kaake R.M.; Richards A.L.; Tutuncuoglu B.; Foussard H.; Batra J.; Haas K.; Modak M.; Kim M.; Haas P.; Polacco B.J.; Braberg H.; Fabius J.M.; Eckhardt M.; Soucheray M.; Bennett M.J.; Cakir M.; McGregor M.J.; Li Q.; Meyer B.; Roesch F.; Vallet T.; Mac Kain A.; Miorin L.; Moreno E.; Naing Z.Z.C.; Zhou Y.; Peng S.; Shi Y.; Zhang Z.; Shen W.; Kirby I.T.; Melnyk J.E.; Chorba J.S.; Lou K.; Dai S.A.; Barrio-Hernandez I.; Memon D.; Hernandez-Armenta C.; Lyu J.; Mathy C.J.P.; Perica T.; Pilla K.B.; Ganesan S.J.; Saltzberg D.J.; Rakesh R.; Liu X.; Rosenthal S.B.; Calviello L.; Venkataramanan S.; Liboy-Lugo J.; Lin Y.; Huang X.P.; Liu Y.; Wankowicz S.A.; Bohn M.; Safari M.; Ugur F.S.; Koh C.; Savar N.S.; Tran Q.D.; Shengjuler D.; Fletcher S.J.; O\u2019Neal M.C.; Cai Y.; Chang J.C.J.; Broadhurst D.J.; Klippsten S.; Sharp P.P.; Wenzell N.A.; Kuzuoglu-Ozturk D.; Wang H.Y.; Trenker R.; Young J.M.; Cavero D.A.; Hiatt J.; Roth T.L.; Rathore U.; Subramanian A.; Noack J.; Hubert M.; Stroud R.M.; Frankel A.D.; Rosenberg O.S.; Verba K.A.; Agard D.A.; Ott M.; Emerman M.; Jura N.; von Zastrow M.; Verdin E.; Ashworth A.; Schwartz O.; d\u2019Enfert C.; Mukherjee S.; Jacobson M.; Malik H.S.; Fujimori D.G.; Ideker T.; Craik C.S.; Floor S.N.; Fraser J.S.; Gross J.D.; Sali A.; Roth B.L.; Ruggero D.; Taunton J.; Kortemme T.; Beltrao P.; Vignuzzi M.; Garc&#xED;a-Sastre A.; Shokat K.M.; Shoichet B.K.; Krogan N.J.; A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature 2020,583(7816),459-468","journal-title":"Nature"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/s41579-019-0288-0","volume":"18","author":"Theuretzbacher U.","year":"2020","unstructured":"Theuretzbacher U.; Outterson K.; Engel A.; Karl&#xE9;n A.; The global preclinical antibacterial pipeline. Nat Rev Microbiol 2020,18(5),275-285","journal-title":"Nat Rev Microbiol"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1038\/s41564-019-0357-1","volume":"4","author":"Farha M.A.","year":"2019","unstructured":"Farha M.A.; Brown E.D.; Drug repurposing for antimicrobial discovery. Nat Microbiol 2019,4(4),565-577","journal-title":"Nat Microbiol"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"61","DOI":"10.4102\/jsava.v70i2.756","volume":"70","author":"Swan G.E.","year":"1999","unstructured":"Swan G.E.; The pharmacology of halogenated salicylanilides and their anthelmintic use in animals : Review article. J S Afr Vet Assoc 1999,70(2),61-70","journal-title":"J S Afr Vet Assoc"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"2604","DOI":"10.1021\/acs.molpharmaceut.5b00098","volume":"12","author":"Costabile G.","year":"2015","unstructured":"Costabile G.; d\u2019Angelo I.; Rampioni G.; Bond&#xEC; R.; Pompili B.; Ascenzioni F.; Mitidieri E.; d\u2019Emmanuele di Villa Bianca R.; Sorrentino R.; Miro A.; Quaglia F.; Imperi F.; Leoni L.; Ungaro F.; Toward repositioning niclosamide for antivirulence therapy of Pseudomonas aeruginosa lung infections: Development of inhalable formulations through nanosuspension technology. Mol Pharm 2015,12(8),2604-2617","journal-title":"Mol Pharm"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1128\/AAC.01952-12","volume":"57","author":"Imperi F.","year":"2013","unstructured":"Imperi F.; Massai F.; Ramachandran Pillai C.; Longo F.; Zennaro E.; Rampioni G.; Visca P.; Leoni L.; New life for an old drug: The anthelmintic drug niclosamide inhibits Pseudomonas aeruginosa quorum sensing. Antimicrob Agents Chemother 2013,57(2),996-1005","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"5233","DOI":"10.1038\/s41467-018-07705-w","volume":"9","author":"Tam J.","year":"2018","unstructured":"Tam J.; Hamza T.; Ma B.; Chen K.; Beilhartz G.L.; Ravel J.; Feng H.; Melnyk R.A.; Host-targeted niclosamide inhibits C. difficile virulence and prevents disease in mice without disrupting the gut microbiota. Nat Commun 2018,9(1),5233","journal-title":"Nat Commun"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/j.bmcl.2019.03.032","volume":"29","author":"Xu J.","year":"2019","unstructured":"Xu J.; Pach&#xF3;n-Ib&#xE1;&#xF1;ez M.E.; Cebrero-Cangueiro T.; Chen H.; S&#xE1;nchez-C&#xE9;spedes J.; Zhou J.; Discovery of niclosamide and its O-alkylamino-tethered derivatives as potent antibacterial agents against carbapenemase-producing and\/or colistin resistant Enterobacteriaceae isolates. Bioorg Med Chem Lett 2019,29(11),1399-1402","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"e01296-18","DOI":"10.1128\/AAC.01296-18","volume":"62","author":"D\u2019Angelo F.","year":"2018","unstructured":"D\u2019Angelo F.; Baldelli V.; Halliday N.; Pantalone P.; Polticelli F.; Fiscarelli E.; Williams P.; Visca P.; Leoni L.; Rampioni G.; Identification of FDA-approved drugs as antivirulence agents targeting the pqs quorum sensing system of Pseudomonas aeruginosa. Antimicrob Agents Chemother 2018,62(11),e01296-18","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"201","DOI":"10.15171\/bi.2018.23","volume":"8","author":"Singh S.","year":"2018","unstructured":"Singh S.; Bhatia S.; In silico identification of albendazole as a quorum sensing inhibitor and its in vitro verification using CviR and LasB receptors based assay systems. Bioimpacts 2018,8(3),201-209","journal-title":"Bioimpacts"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1007\/s10096-020-03882-z","volume":"39","author":"Seleem N.M.","year":"2020","unstructured":"Seleem N.M.; Abd El Latif H.K.; Shaldam M.A.; El-Ganiny A.; Drugs with new lease of life as quorum sensing inhibitors: For combating MDR Acinetobacter baumannii infections. Eur J Clin Microbiol Infect Dis 2020,39(9),1687-1702","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"4369","DOI":"10.1128\/AAC.00583-11","volume":"55","author":"Sambanthamoorthy K.","year":"2011","unstructured":"Sambanthamoorthy K.; Gokhale A.A.; Lao W.; Parashar V.; Neiditch M.B.; Semmelhack M.F.; Lee I.; Waters C.M.; Identification of a novel benzimidazole that inhibits bacterial biofilm formation in a broad-spectrum manner. Antimicrob Agents Chemother 2011,55(9),4369-4378","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1080\/08927014.2018.1564818","volume":"35","author":"Czerwonka G.","year":"2019","unstructured":"Czerwonka G.; Gmiter D.; Guzy A.; Rogala P.; Jab\u0142o\u0144ska-Wawrzycka A.; Borkowski A.; C\u0142apa T.; Naro&#x17C;na D.; Kowalczyk P.; Syczewski M.; Drabik M.; Da\u0144czuk M.; Kaca W.; A benzimidazole-based ruthenium(IV) complex inhibits Pseudomonas aeruginosa biofilm formation by interacting with siderophores and the cell envelope, and inducing oxidative stress. Biofouling 2019,35(1),59-74","journal-title":"Biofouling"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"887","DOI":"10.2217\/fmb.14.46","volume":"9","author":"Steadman D.","year":"2014","unstructured":"Steadman D.; Lo A.; Waksman G.; Remaut H.; Bacterial surface appendages as targets for novel antibacterial therapeutics. Future Microbiol 2014,9(7),887-900","journal-title":"Future Microbiol"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1128\/AAC.02221-15","volume":"60","author":"Chahales P.","year":"2016","unstructured":"Chahales P.; Hoffman P.S.; Thanassi D.G.; Nitazoxanide inhibits pilus biogenesis by interfering with folding of the usher protein in the outer membrane. Antimicrob Agents Chemother 2016,60(4),2028-2038","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"14357","DOI":"10.1074\/jbc.RA119.009616","volume":"294","author":"Psonis J.J.","year":"2019","unstructured":"Psonis J.J.; Chahales P.; Henderson N.S.; Rigel N.W.; Hoffman P.S.; Thanassi D.G.; The small molecule nitazoxanide selectively disrupts BAM-mediated folding of the outer membrane usher protein. J Biol Chem 2019,294(39),14357-14369","journal-title":"J Biol Chem"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1128\/AAC.01279-09","volume":"54","author":"Shamir E.R.","year":"2010","unstructured":"Shamir E.R.; Warthan M.; Brown S.P.; Nataro J.P.; Guerrant R.L.; Hoffman P.S.; Nitazoxanide inhibits biofilm production and hemagglutination by enteroaggregative Escherichia coli strains by blocking assembly of AafA fimbriae. Antimicrob Agents Chemother 2010,54(4),1526-1533","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"348","DOI":"10.3389\/fcimb.2018.00348","volume":"8","author":"Ayerbe-Algaba R.","year":"2018","unstructured":"Ayerbe-Algaba R.; Gil-Marqu&#xE9;s M.L.; Jim&#xE9;nez-Mej&#xED;as M.E.; S&#xE1;nchez-Encinales V.; Parra-Mill&#xE1;n R.; Pach&#xF3;n-Ib&#xE1;&#xF1;ez M.E.; Pach&#xF3;n J.; Smani Y.; Synergistic activity of niclosamide in combination with colistin against colistin-susceptible and colistin-resistant Acinetobacter baumannii and Klebsiella pneumoniae. Front Cell Infect Microbiol 2018,8,348","journal-title":"Front Cell Infect Microbiol"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1093\/jac\/dkaa103","volume":"75","author":"Mir&#xF3;-Canturri A.","year":"2020","unstructured":"Mir&#xF3;-Canturri A.; Ayerbe-Algaba R.; Villodres &#xC1;.R.; Pach&#xF3;n J.; Smani Y.; Repositioning rafoxanide to treat Gram-negative bacilli infections. J Antimicrob Chemother 2020,75(7),1895-1905","journal-title":"J Antimicrob Chemother"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1093\/jac\/dky545","volume":"74","author":"Maiden M.M.","year":"2019","unstructured":"Maiden M.M.; Zachos M.P.; Waters C.M.; The ionophore oxyclozanide enhances tobramycin killing of Pseudomonas aeruginosa biofilms by permeabilizing cells and depolarizing the membrane potential. J Antimicrob Chemother 2019,74(4),894-906","journal-title":"J Antimicrob Chemother"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.ijantimicag.2019.07.006","volume":"54","author":"Ayerbe-Algaba R.","year":"2019","unstructured":"Ayerbe-Algaba R.; Gil-Marqu&#xE9;s M.L.; Mir&#xF3;-Canturri A.; Parra-Mill&#xE1;n R.; Pach&#xF3;n-Ib&#xE1;&#xF1;ez M.E.; Jim&#xE9;nez-Mej&#xED;as M.E.; Pach&#xF3;n J.; Smani Y.; The anthelmintic oxyclozanide restores the activity of colistin against colistin-resistant Gram-negative bacilli. Int J Antimicrob Agents 2019,54(4),507-512","journal-title":"Int J Antimicrob Agents"},{"key":"ref=33","author":"Mir&#xF3;-Canturri A.","year":"2019","unstructured":"Mir&#xF3;-Canturri A.; Ayerbe-Algaba R.; Pach&#xF3;n-Ib&#xE1;&#xF1;ez M.E.; Pachon-D&#xED;az J.; Smani Y.; In vitro activity of ivermectin in combination with colistin against Gram negative bacilli. 29 European Congress of Clinical Microbiology and Infectious Diseases 2019","journal-title":"29 European Congress of Clinical Microbiology and Infectious Diseases"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"e02068-20","DOI":"10.1128\/mBio.02068-20","volume":"11","author":"Copp J.N.","year":"2020","unstructured":"Copp J.N.; Pletzer D.; Brown A.S.; Van der Heijden J.; Miton C.M.; Edgar R.J.; Rich M.H.; Little R.F.; Williams E.M.; Hancock R.E.W.; Tokuriki N.; Ackerley D.F.; Mechanistic understanding enables the rational design of salicylanilide combination therapies for Gram-negative infections. MBio 2020,11(5),e02068-20","journal-title":"MBio"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.cellimm.2013.12.006","volume":"288","author":"Wu C.S.","year":"2014","unstructured":"Wu C.S.; Li Y.R.; Chen J.J.W.; Chen Y.C.; Chu C.L.; Pan I.H.; Wu Y.S.; Lin C.C.; Antihelminthic niclosamide modulates dendritic cells activation and function. Cell Immunol 2014,288(1-2),15-23","journal-title":"Cell Immunol"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1007\/s00011-008-8007-8","volume":"57","author":"Zhang X.","year":"2008","unstructured":"Zhang X.; Song Y.; Ci X.; An N.; Ju Y.; Li H.; Wang X.; Han C.; Cui J.; Deng X.; Ivermectin inhibits LPS-induced production of inflammatory cytokines and improves LPS-induced survival in mice. Inflamm Res 2008,57(11),524-529","journal-title":"Inflamm Res"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.intimp.2008.12.016","volume":"9","author":"Zhang X.","year":"2009","unstructured":"Zhang X.; Song Y.; Xiong H.; Ci X.; Li H.; Yu L.; Zhang L.; Deng X.; Inhibitory effects of ivermectin on nitric oxide and prostaglandin E2 production in LPS-stimulated RAW 264.7 macrophages. Int Immunopharmacol 2009,9(3),354-359","journal-title":"Int Immunopharmacol"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"e99431","DOI":"10.1172\/jci.insight.99431","volume":"3","author":"Cs&#xF3;ka B.","year":"2018","unstructured":"Cs&#xF3;ka B.; N&#xE9;meth Z.H.; Szab&#xF3; I.; Davies D.L.; Varga Z.V.; P&#xE1;l&#xF3;czi J.; Falzoni S.; Di Virgilio F.; Muramatsu R.; Yamashita T.; Pacher P.; Hask&#xF3; G.; Macrophage P2X4 receptors augment bacterial killing and protect against sepsis. JCI Insight 2018,3(11),e99431","journal-title":"JCI Insight"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1111\/j.1472-8206.2010.00896.x","volume":"25","author":"Zhang X.","year":"2011","unstructured":"Zhang X.; Li J.; Chen C.; Ci X.; Yu Q.; Zhang X.; Deng X.; Protective effect of abamectin on acute lung injury induced by lipopolysaccharide in mice. Fundam Clin Pharmacol 2011,25(6),700-707","journal-title":"Fundam Clin Pharmacol"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1097\/QCO.0000000000000518","volume":"32","author":"Garnacho-Montero J.","year":"2019","unstructured":"Garnacho-Montero J.; Timsit J.F.; Managing Acinetobacter baumannii infections. Curr Opin Infect Dis 2019,32(1),69-76","journal-title":"Curr Opin Infect Dis"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1086\/374337","volume":"36","author":"Garnacho-Montero J.","year":"2003","unstructured":"Garnacho-Montero J.; Ortiz-Leyba C.; Jim&#xE9;nez-Jim&#xE9;nez F.J.; Barrero-Almod&#xF3;var A.E.; Garc&#xED;a-Garmendia J.L.; Bernabeu-WittelI M.; Gallego-Lara S.L.; Madrazo-Osuna J.; Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: A comparison with imipenem-susceptible VAP. Clin Infect Dis 2003,36(9),1111-1118","journal-title":"Clin Infect Dis"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.clinthera.2008.01.015","volume":"30","author":"Markou N.","year":"2008","unstructured":"Markou N.; Markantonis S.L.; Dimitrakis E.; Panidis D.; Boutzouka E.; Karatzas S.; Rafailidis P.; Apostolakos H.; Baltopoulos G.; Colistin serum concentrations after intravenous administration in critically ill patients with serious multidrug-resistant, gram-negative bacilli infections: A prospective, open-label, uncontrolled study. Clin Ther 2008,30(1),143-151","journal-title":"Clin Ther"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"e0168468","DOI":"10.1371\/journal.pone.0168468","volume":"11","author":"&#xC1;lvarez-Mar&#xED;n R.","year":"2016","unstructured":"&#xC1;lvarez-Mar&#xED;n R.; L&#xF3;pez-Rojas R.; M&#xE1;rquez J.A.; G&#xF3;mez M.J.; Molina J.; Cisneros J.M.; Ortiz-Leyba C.; Aznar J.; Garnacho-Montero J.; Pach&#xF3;n J.; Colistin dosage without loading dose is efficacious when treating carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia caused by strains with high susceptibility to colistin. PLoS One 2016,11(12),e0168468","journal-title":"PLoS One"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"e02574-18","DOI":"10.1128\/AAC.02574-18","volume":"63","author":"Domalaon R.","year":"2019","unstructured":"Domalaon R.; De Silva P.M.; Kumar A.; Zhanel G.G.; Schweizer F.; The anthelmintic drug niclosamide synergizes with colistin and reverses colistin resistance in Gram-negative bacilli. Antimicrob Agents Chemother 2019,63(4),e02574-18","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/s41429-019-0186-8","volume":"72","author":"Domalaon R.","year":"2019","unstructured":"Domalaon R.; Okunnu O.; Zhanel G.G.; Schweizer F.; Synergistic combinations of anthelmintic salicylanilides oxyclozanide, rafoxanide, and closantel with colistin eradicates multidrug-resistant colistin-resistant Gram-negative bacilli. J Antibiot (Tokyo) 2019,72(8),605-616","journal-title":"J Antibiot (Tokyo)"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/ja.2015.127","volume":"69","author":"Tran T.B.","year":"2016","unstructured":"Tran T.B.; Cheah S.E.; Yu H.H.; Bergen P.J.; Nation R.L.; Creek D.J.; Purcell A.; Forrest A.; Doi Y.; Song J.; Velkov T.; Li J.; Anthelmintic closantel enhances bacterial killing of polymyxin B against multidrug-resistant Acinetobacter baumannii. J Antibiot (Tokyo) 2016,69(6),415-421","journal-title":"J Antibiot (Tokyo)"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"335","DOI":"10.3390\/antibiotics11030335","volume":"11","author":"Schweizer L.","year":"2022","unstructured":"Schweizer L.; Ramirez D.; Schweizer F.; Effects of lysine N-zeta-methylation in ultrashort tetrabasic lipopeptides (UTBLPs) on the potentiation of rifampicin, novobiocin, and niclosamide in Gram-negative bacteria. Antibiotics (Basel) 2022,11(3),335","journal-title":"Antibiotics (Basel)"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"111850","DOI":"10.1016\/j.ejmech.2019.111850","volume":"186","author":"Dokla E.M.E.","year":"2020","unstructured":"Dokla E.M.E.; Abutaleb N.S.; Milik S.N.; Li D.; El-Baz K.; Shalaby M.A.W.; Al-Karaki R.; Nasr M.; Klein C.D.; Abouzid K.A.M.; Seleem M.N.; Development of benzimidazole-based derivatives as antimicrobial agents and their synergistic effect with colistin against gram-negative bacteria. Eur J Med Chem 2020,186,111850","journal-title":"Eur J Med Chem"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1111\/2049-632X.12033","volume":"67","author":"Gellatly S.L.","year":"2013","unstructured":"Gellatly S.L.; Hancock R.E.W.; Pseudomonas aeruginosa: New insights into pathogenesis and host defenses. Pathog Dis 2013,67(3),159-173","journal-title":"Pathog Dis"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1086\/377200","volume":"37","author":"Kang C.I.","year":"2003","unstructured":"Kang C.I.; Kim S.H.; Kim H.B.; Park S.W.; Choe Y.J.; Oh M.; Kim E.C.; Choe K.W.; Pseudomonas aeruginosa bacteremia: Risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome. Clin Infect Dis 2003,37(6),745-751","journal-title":"Clin Infect Dis"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1001\/archinte.1996.00440170139015","volume":"156","author":"Vidal F.","year":"1996","unstructured":"Vidal F.; Mensa J.; Almela M.; Mart&#xED;nez J.A.; Marco F.; Casals C.; Gatell J.M.; Soriano E.; Jimenez de Anta M.T.; Epidemiology and outcome of Pseudomonas aeruginosa bacteremia, with special emphasis on the influence of antibiotic treatment. Analysis of 189 episodes. Arch Intern Med 1996,156(18),2121-2126","journal-title":"Arch Intern Med"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1016\/S0140-6736(03)13644-6","volume":"361","author":"Vincent J.L.","year":"2003","unstructured":"Vincent J.L.; Nosocomial infections in adult intensive-care units. Lancet 2003,361(9374),2068-2077","journal-title":"Lancet"},{"key":"ref=53","first-page":"12","volume":"65","author":"Ali Z.","year":"2015","unstructured":"Ali Z.; Mumtaz N.; Naz S.A.; Jabeen N.; Shafique M.; Multi-drug resistant pseudomonas aeruginosa: A threat of nosocomial infections in tertiary care hospitals. J Pak Med Assoc 2015,65(1),12-16","journal-title":"J Pak Med Assoc"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1186\/s13054-015-0926-5","volume":"19","author":"Micek S.T.","year":"2015","unstructured":"Micek S.T.; Wunderink R.G.; Kollef M.H.; Chen C.; Rello J.; Chastre J.; Antonelli M.; Welte T.; Clair B.; Ostermann H.; Calbo E.; Torres A.; Menichetti F.; Schramm G.E.; Menon V.; An international multicenter retrospective study of Pseudomonas aeruginosa nosocomial pneumonia: Impact of multidrug resistance. Crit Care 2015,19(1),219","journal-title":"Crit Care"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1002\/phar.1636","volume":"35","author":"Kaye K.S.","year":"2015","unstructured":"Kaye K.S.; Pogue J.M.; Infections caused by resistant Gram-negative bacteria: Epidemiology and management. Pharmacotherapy 2015,35(10),949-962","journal-title":"Pharmacotherapy"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/j.cmi.2017.09.001","volume":"23","author":"Wright H.","year":"2017","unstructured":"Wright H.; Bonomo R.A.; Paterson D.L.; New agents for the treatment of infections with Gram-negative bacteria: Restoring the miracle or false dawn? Clin Microbiol Infect 2017,23(10),704-712","journal-title":"Clin Microbiol Infect"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"114318","DOI":"10.1016\/j.ejmech.2022.114318","volume":"236","author":"Lu T.","year":"2022","unstructured":"Lu T.; Zheng X.; Mao F.; Cao Q.; Cao Q.; Zhu J.; Li X.; Lan L.; Li B.; Li J.; Novel niclosamide-derived adjuvants elevating the efficacy of polymyxin B against MDR Pseudomonas aeruginosa DK2. Eur J Med Chem 2022,236,114318","journal-title":"Eur J Med Chem"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1039\/D1MD00206F","volume":"12","author":"Berry L.","year":"2021","unstructured":"Berry L.; Brizuela M.; Jackson G.; Schweizer F.; A niclosamide\u2013tobramycin hybrid adjuvant potentiates cefiderocol against P. aeruginosa. RSC Medicinal Chemistry 2021,12(9),1565-1573","journal-title":"RSC Medicinal Chemistry"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1093\/femsre\/fuw005","volume":"40","author":"Vila J.","year":"2016","unstructured":"Vila J.; S&#xE1;ez-L&#xF3;pez E.; Johnson J.R.; R&#xF6;mling U.; Dobrindt U.; Cant&#xF3;n R.; Giske C.G.; Naas T.; Carattoli A.; Mart&#xED;nez-Medina M.; Bosch J.; Retamar P.; Rodr&#xED;guez-Ba&#xF1;o J.; Baquero F.; Soto S.M.; Escherichia coli : An old friend with new tidings. FEMS Microbiol Rev 2016,40(4),437-463","journal-title":"FEMS Microbiol Rev"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"e00135-18","DOI":"10.1128\/CMR.00135-18","volume":"32","author":"Manges A.R.","year":"2019","unstructured":"Manges A.R.; Geum H.M.; Guo A.; Edens T.J.; Fibke C.D.; Pitout J.D.D.; Globalextraintestinal pathogenic Escherichia coli (ExPEC) lineages. Clin Microbiol Rev 2019,32(3),e00135-18","journal-title":"Clin Microbiol Rev"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1086\/649554","volume":"50","author":"Solomkin J.S.","year":"2010","unstructured":"Solomkin J.S.; Mazuski J.E.; Bradley J.S.; Rodvold K.A.; Goldstein E.J.C.; Baron E.J.; O\u2019Neill P.J.; Chow A.W.; Dellinger E.P.; Eachempati S.R.; Gorbach S.; Hilfiker M.; May A.K.; Nathens A.B.; Sawyer R.G.; Bartlett J.G.; Diagnosis and management of complicated intra-abdominal infection in adults and children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis 2010,50(2),133-164","journal-title":"Clin Infect Dis"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1128\/MMBR.00078-15","volume":"80","author":"Paczosa M.K.","year":"2016","unstructured":"Paczosa M.K.; Mecsas J.; Klebsiella pneumoniae: Going on the offense with a strong defense. Microbiol Mol Biol Rev 2016,80(3),629-661","journal-title":"Microbiol Mol Biol Rev"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1128\/CMR.00064-16","volume":"30","author":"Poirel L.","year":"2017","unstructured":"Poirel L.; Jayol A.; Nordmann P.; Polymyxins: Antibacterial activity, susceptibility testing, and resistance mechanisms encoded by plasmids or chromosomes. Clin Microbiol Rev 2017,30(2),557-596","journal-title":"Clin Microbiol Rev"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"3303","DOI":"10.1021\/acsinfecdis.1c00463","volume":"7","author":"Li H.","year":"2021","unstructured":"Li H.; Mattingly A.E.; Jania L.A.; Smith R.; Melander R.J.; Ernst R.K.; Koller B.H.; Melander C.; Benzimidazole isosteres of salicylanilides are highly active colistin adjuvants. ACS Infect Dis 2021,7(12),3303-3313","journal-title":"ACS Infect Dis"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1093\/jac\/dkac044","volume":"77","author":"Pacios O.","year":"2022","unstructured":"Pacios O.; Fern&#xE1;ndez-Garc&#xED;a L.; Bleriot I.; Blasco L.; Ambroa A.; L&#xF3;pez M.; Ortiz-Cartagena C.; Gonz&#xE1;lez de Aledo M.; Fern&#xE1;ndez-Cuenca F.; Oteo-Iglesias J.; Pascual &#xC1;.; Mart&#xED;nez-Mart&#xED;nez L.; Tom&#xE1;s M.; Adaptation of clinical isolates of Klebsiella pneumoniae to the combination of niclosamide with the efflux pump inhibitor phenyl-arginine-&#x3B2;-naphthylamide (Pa&#x3B2;N): Co-resistance to antimicrobials. J Antimicrob Chemother 2022,77(5),1272-1281","journal-title":"J Antimicrob Chemother"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"4935","DOI":"10.3390\/molecules26164935","volume":"26","author":"Racan&#xE9; L.","year":"2021","unstructured":"Racan&#xE9; L.; Zlatar I.; Perin N.; Cindri\u0107 M.; Radovanovi\u0107 V.; Banjanac M.; Shanmugam S.; Stojkovi\u0107 M.R.; Braj\u0161a K.; Hranjec M.; Biological activity of newly synthesized benzimidazole and benzothizole 2,5- disubstituted furane derivatives. Molecules 2021,26(16),4935","journal-title":"Molecules"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"105227","DOI":"10.1016\/j.bioorg.2021.105227","volume":"115","author":"Chaurasia H.","year":"2021","unstructured":"Chaurasia H.; Singh V.K.; Mishra R.; Yadav A.K.; Ram N.K.; Singh P.; Singh R.K.; Molecular modelling, synthesis and antimicrobial evaluation of benzimidazole nucleoside mimetics. Bioorg Chem 2021,115,105227","journal-title":"Bioorg Chem"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1099\/jmm.0.046300-0","volume":"62","author":"Bolick D.T.","year":"2013","unstructured":"Bolick D.T.; Roche J.K.; Hontecillas R.; Bassaganya-Riera J.; Nataro J.P.; Guerrant R.L.; Enteroaggregative Escherichia coli strain in a novel weaned mouse model: Exacerbation by malnutrition, biofilm as a virulence factor and treatment by nitazoxanide. J Med Microbiol 2013,62(6),896-905","journal-title":"J Med Microbiol"},{"key":"ref=69","author":"Grayson M.L.","unstructured":"Grayson M.L.; Cosgrove S.E.; Crowe S.; Hope W.; McCarthy J.S.; Mills J.;  Kucers\u2019 The use of antibiotics: A clinical review of antibacterial, antifungal, antiparasitic and antiviral drugs 7th; 2017, pp. 1-4841.","journal-title":"Kucers\u2019 The use of antibiotics: A clinical review of antibacterial, antifungal, antiparasitic and antiviral drugs"},{"key":"ref=70","year":"2017","unstructured":"Niclosamide for mild to moderate COVID-19. 2017"},{"key":"ref=71","year":"2017","unstructured":"Sars-CoV-2\/COVID-19 Ivermectin Navarra-ISGlobal Trial (SAINT). 2017"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1086\/506351","volume":"43","author":"Musher D.M.","year":"2006","unstructured":"Musher D.M.; Logan N.; Hamill R.J.; DuPont H.L.; Lentnek A.; Gupta A.; Rossignol J.F.; Nitazoxanide for the treatment of Clostridium difficile colitis. Clin Infect Dis 2006,43(4),421-427","journal-title":"Clin Infect Dis"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"e41","DOI":"10.1086\/596552","volume":"48","author":"Musher D.M.","year":"2009","unstructured":"Musher D.M.; Logan N.; Bressler A.M.; Johnson D.P.; Rossignol J.F.; Nitazoxanide versus vancomycin in Clostridium difficile infection: A randomized, double-blind study. Clin Infect Dis 2009,48(4),e41-e46","journal-title":"Clin Infect Dis"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1080\/23744235.2019.1708454","volume":"52","author":"Lee S.","year":"2020","unstructured":"Lee S.; Sneed G.T.; Brown J.N.; Treatment of Helicobacter pylori with nitazoxanide-containing regimens: A systematic review. Infect Dis (Lond) 2020,52(6),381-390","journal-title":"Infect Dis (Lond)"},{"key":"ref=75","year":"2017","unstructured":"A unique regimen for treatment of Helicobacter pylori infection. 2017"},{"key":"ref=76","year":"2017","unstructured":"Study of nitazoxanide (NTZ) for Helicobacter pylori in children. 2017"},{"key":"ref=77","year":"2017","unstructured":"Inhaled sodium nitrite as an antimicrobial for cystic fibrosis. 2017"},{"key":"ref=78","unstructured":"Reducing antibiotic tolerance using nitric oxide in CF - a phase 2 pilot study (RATNO)."},{"key":"ref=79","year":"2011","unstructured":"Atorvastatin in bronchiectasis in patients with Pseudomonas aeruginosa. 2011"},{"key":"ref=80","year":"2017","unstructured":"Anti-inflammatory effects of GTS-21 after LPS. 2017"}],"container-title":["Current Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0929867329666220714092916","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/206776\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0929867329666220714092916","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T15:52:46Z","timestamp":1693669966000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/206776\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":80,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0929867329666220714092916","relation":{},"ISSN":["0929-8673"],"issn-type":[{"value":"0929-8673","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2021-12-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-06","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-12-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}